表紙
市場調査レポート

H5N1感染症(鳥インフルエンザ):パイプライン分析

H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016

発行 Global Markets Direct 商品コード 245964
出版日 ページ情報 英文 208 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
H5N1感染症(鳥インフルエンザ):パイプライン分析 H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016
出版日: 2016年05月25日 ページ情報: 英文 208 Pages
概要

H5N1感染症は、感染性の強いインフルエンザウイルスの一種で、鳥インフルエンザとも呼ばれ、重度の呼吸器疾患を引き起こします。このウイルスはヒトに伝染します。発熱、咳、急性呼吸促迫、息切れ/呼吸困難、腹痛、下痢などの症状が見られます。素因として、家禽を扱う仕事、感染した鳥への接触、生または加熱が不十分な鶏肉の摂食が挙げられます。抗ウイルス薬などで治療します。

当レポートでは、H5N1感染症(鳥インフルエンザ)に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

目次

イントロダクション

H5N1感染症(鳥インフルエンザ)の概要

治療薬の開発

  • パイプライン製品:概要
  • パイプライン製品:比較分析

開発中の治療薬:企業別

調査中の治療薬:大学/研究機関別

パイプライン製品の概要

  • 後期段階の製品
  • 治験段階の製品
  • 初期段階の製品

開発中の製品:企業別

調査中の製品:大学/研究機関別

治療薬の開発に従事している企業

  • Akshaya Bio Inc.
  • Altimmune, Inc.
  • Antigen Express, Inc.
  • Aphios Corporation
  • BioDiem Ltd
  • BiondVax Pharmaceuticals Ltd.
  • CEL-SCI Corporation
  • Cocrystal Pharma, Inc.
  • CSL Limited
  • 第一三共
  • Emergent BioSolutions Inc.
  • Gemmus Pharma Inc.
  • GlaxoSmithKline Plc
  • Hemispherx Biopharma, Inc.
  • iBio, Inc.
  • Immunovaccine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • Johnson & Johnson
  • Kineta, Inc.
  • Medicago Inc.
  • MedImmune, LLC
  • Microbiotix, Inc.
  • NanoBio Corporation
  • Nanotherapeutics, Inc
  • NanoViricides, Inc.
  • NewLink Genetics Corporation
  • OPKO Health, Inc.
  • PaxVax, Inc.
  • PeptiDream Inc.
  • Protein Sciences Corporation
  • 塩野義製薬
  • Sirnaomics, Inc.
  • 武田薬品工業
  • TechnoVax, Inc.
  • TGV-Laboratories
  • Theraclone Sciences, Inc.
  • Vaxine Pty Ltd .
  • VaxInnate Corporation

治療薬の評価

  • 単独療法の場合
  • 併用療法の場合
  • 標的別
  • 作用機序別
  • 投与経路別
  • 分子タイプ別

薬剤のプロファイル

パイプライン製品の最新動向

休止状態のプロジェクト

開発が中止された製品

製品開発のマイルストーン

  • 最新ニュースとプレスリリース

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC8005IDB

Summary

Global Markets Direct's, 'H5N1 Infection (Avian Influenza) - Pipeline Review, H1 2016', provides an overview of the H5N1 Infection (Avian Influenza) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for H5N1 Infection (Avian Influenza), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for H5N1 Infection (Avian Influenza) and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape of H5N1 Infection (Avian Influenza)
  • The report reviews pipeline therapeutics for H5N1 Infection (Avian Influenza) by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved H5N1 Infection (Avian Influenza) therapeutics and enlists all their major and minor projects
  • The report assesses H5N1 Infection (Avian Influenza) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news related to pipeline therapeutics for H5N1 Infection (Avian Influenza)

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of therapeutics under development for H5N1 Infection (Avian Influenza)
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding H5N1 Infection (Avian Influenza) pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

  • Table of Contents
  • Introduction
  • H5N1 Infection (Avian Influenza) Overview
  • Therapeutics Development
  • H5N1 Infection (Avian Influenza) - Therapeutics under Development by Companies
  • H5N1 Infection (Avian Influenza) - Therapeutics under Investigation by Universities/Institutes
  • H5N1 Infection (Avian Influenza) - Pipeline Products Glance
  • H5N1 Infection (Avian Influenza) - Products under Development by Companies
  • H5N1 Infection (Avian Influenza) - Products under Investigation by Universities/Institutes
  • H5N1 Infection (Avian Influenza) - Companies Involved in Therapeutics Development
  • H5N1 Infection (Avian Influenza) - Therapeutics Assessment
  • Drug Profiles
  • H5N1 Infection (Avian Influenza) - Recent Pipeline Updates
  • H5N1 Infection (Avian Influenza) - Dormant Projects
  • H5N1 Infection (Avian Influenza) - Discontinued Products
  • H5N1 Infection (Avian Influenza) - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2016
  • Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Development by Companies, H1 2016 (Contd..1)
  • Number of Products under Development by Companies, H1 2016 (Contd..2)
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Development, H1 2016
  • Products under Development by Companies, H1 2016
  • Products under Development by Companies, H1 2016 (Contd..1)
  • Products under Development by Companies, H1 2016 (Contd..2)
  • Products under Development by Companies, H1 2016 (Contd..3)
  • Products under Investigation by Universities/Institutes, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Akshaya Bio Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Altimmune, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Antigen Express, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Aphios Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by BioDiem Ltd, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by BiondVax Pharmaceuticals Ltd., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by CEL-SCI Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Cocrystal Pharma, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by CSL Limited, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Daiichi Sankyo Company, Limited, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Emergent BioSolutions Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Gemmus Pharma Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by GlaxoSmithKline Plc, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Hemispherx Biopharma, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by iBio, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Immunovaccine, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Inovio Pharmaceuticals, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Johnson & Johnson, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Kineta, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Medicago Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by MedImmune, LLC, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Microbiotix, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by NanoBio Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Nanotherapeutics, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by NanoViricides, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by NewLink Genetics Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by OPKO Health, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by PaxVax, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by PeptiDream Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Protein Sciences Corporation, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Shionogi & Co., Ltd., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Sirnaomics, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by TechnoVax, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by TGV-Laboratories, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Theraclone Sciences, Inc., H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by Vaxine Pty Ltd, H1 2016
  • H5N1 Infection (Avian Influenza) - Pipeline by VaxInnate Corporation, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Assessment by Combination Products, H1 2016
  • Number of Products by Stage and Target, H1 2016
  • Number of Products by Stage and Mechanism of Action, H1 2016
  • Number of Products by Stage and Route of Administration, H1 2016
  • Number of Products by Stage and Molecule Type, H1 2016
  • H5N1 Infection (Avian Influenza) Therapeutics - Recent Pipeline Updates, H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects, H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..1), H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..2), H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..3), H1 2016
  • H5N1 Infection (Avian Influenza) - Dormant Projects (Contd..4), H1 2016
  • H5N1 Infection (Avian Influenza) - Discontinued Products, H1 2016

List of Figures

  • Number of Products under Development for H5N1 Infection (Avian Influenza), H1 2016
  • Number of Products under Development for H5N1 Infection (Avian Influenza) - Comparative Analysis, H1 2016
  • Number of Products under Development by Companies, H1 2016
  • Number of Products under Investigation by Universities/Institutes, H1 2016
  • Comparative Analysis by Late Stage Development, H1 2016
  • Comparative Analysis by Clinical Stage Development, H1 2016
  • Comparative Analysis by Early Stage Products, H1 2016
  • Assessment by Monotherapy Products, H1 2016
  • Number of Products by Stage and Top 10 Targets, H1 2016
  • Number of Products by Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016
  • Number of Products by Routes of Administration, H1 2016
  • Number of Products by Stage and Routes of Administration, H1 2016
  • Number of Products by Top 10 Molecule Types, H1 2016
  • Number of Products by Stage and Top 10 Molecule Types, H1 2016
Back to Top